



## BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 18, 2026

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website [here](#).

### Details on the presentations are as follows:

- **Title:** The RAS: PI3K $\alpha$  breaker BBO-10203 inhibits PI3K $\alpha$ /AKT activity in HER2+ models through non-canonical RAS signaling blockade
  - **Session Category:** Experimental and Molecular Therapeutics
  - **Session Title:** Targeted Protein Degradation and Non-cannonical Oncogenic Signaling
  - **Session Type:** Oral Presentation
  - **Session Date/Time:** Tuesday, April 21, 2:30 p.m. – 4:30 p.m. PT
  - **Location:** Upper Level Ballroom 6DE
  - **Abstract Number:** 6780
  - **Presenter:** James Stice, PhD, Director, BBOT
- 
- **Title:** BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
  - **Session Category:** Experimental and Molecular Therapeutics
  - **Session Title:** Novel Antitumor Agents 3
  - **Session Type:** Poster Presentation
  - **Session Date/Time:** Wednesday, April 22, 9:00 a.m. – 12:00 p.m. PT
  - **Location:** Poster Section 13
  - **Poster Board Number:** 24
  - **Poster Number:** 7104
  - **Presenter:** Carlos Stahlhut, PhD, Associate Director, BBOT

### About BBO-11818

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS-mutant preclinical models, including KRAS<sup>G12D</sup> and KRAS<sup>G12V</sup>. BBO-11818 potently suppresses MAPK signaling and inhibits cell proliferation in KRAS-mutant cell lines and mouse models. BBO-11818 is currently being evaluated in the Phase 1 [KONQUER-101 trial](#) in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors.

### About BBO-10203

BBO-10203 is a first-in-class small molecule which breaks the protein-protein interaction between RAS and PI3K $\alpha$  and inhibits RAS-mediated activation of the PI3K $\alpha$  pathway. It selectively disrupts oncogenic RAS-PI3K $\alpha$  signaling while sparing insulin-mediated glucose uptake, potentially maintaining efficacy with reduced risk of hyperglycemia or hyperinsulinemia. BBO-10203 is currently being evaluated in the Phase 1 [BREAKER-101 trial](#) for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer.

### About BBOT

BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K $\alpha$  malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit [www.bbotx.com](http://www.bbotx.com) and follow us on [LinkedIn](#).

### BBOT Contacts:

#### Investor Contact:

Heather Armstrong

BBOT

[Heather.Armstrong@bbotx.com](mailto:Heather.Armstrong@bbotx.com)

**Media Contact:**

Jake Robison

Inizio Evoke Comms

[Jake.robison@inizioevoke.com](mailto:Jake.robison@inizioevoke.com)